Ionis Pharmaceuticals (IONS) Accumulated Expenses (2009 - 2026)

Ionis Pharmaceuticals' Accumulated Expenses history runs 18 years deep, the most recent figure standing at $115.8 million for Q2 2026.

• In Q2 2026, Accumulated Expenses rose 17.0% year-over-year to $115.8 million; the TTM figure through Jun 2026 stood at $115.8 million (up 17.0% YoY), while the FY2025 annual figure was $116.2 million, up 7.19% from the prior year.
• Accumulated Expenses for Q2 2026 stood at $115.8 million, down from $126.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $147.9 million in Q4 2023, with the low at $99.0 million in Q2 2025.
• The 5-year median for Accumulated Expenses is $115.1 million (2024), against an average of $116.6 million.
• The sharpest annual moves came in 2022 and 2024: Accumulated Expenses jumped 78.76% in 2022, then declined 26.68% in 2024.
• Ionis Pharmaceuticals' Accumulated Expenses stood at $140.1 million in 2022, then rose by 5.56% to $147.9 million in 2023, then dropped by 26.68% to $108.4 million in 2024, then climbed by 7.19% to $116.2 million in 2025, then declined by 0.39% to $115.8 million in 2026.
• Business Quant data shows IONS's Accumulated Expenses at $115.8 million in Q2 2026, $126.5 million in Q1 2026, and $116.2 million in Q4 2025.